Hello everyone,
here is an overview of the latest developments at Redcare Pharmacy $RDC (-1,29%) formerly known as Shop Apotheke Europe.
📈 Key financial figures (as of Q2 2025)
- Turnover (TTM): USD 1.33 billion
- EBIT (TTM): USD -74.83 million
- Adjusted EBITDA margin (Q2): 2.6%
- Sales growth (Q2 YoY): +26,5 %
- Current share price: approx. EUR 102.70
🔍 Analysis
Strengths:
- Strong sales growth: In the second quarter of 2025, Redcare Pharmacy achieved impressive sales growth of 26.5% year-on-year.
- Adjusted EBITDA margin: Adjusted EBITDA margin increased to 2.6%, the highest level in the last 12 months
- Expansion into international markets: The International segment (Belgium, the Netherlands, France and Italy) grew by 26.2 % to EUR 135 million in the first quarter of 2025.
Challenges:
- Unprofitability: Despite sales growth, the company remains negative in terms of EBIT.
- Regulatory uncertainties: The pharmacy market is highly regulated, particularly in Europe, which poses potential risks.
- Competitive pressure: The online pharmacy market is highly competitive, which can lead to pressure on margins.()
📌 Conclusion
Redcare Pharmacy shows solid growth figures and a positive development in international markets. The rising EBITDA margin indicates progress in profitability. However, the company is still in negative territory in terms of EBIT, which could continue to make investors cautious.
What do you think about the current development of Redcare Pharmacy? Do you see potential for sustainable profitability? $RDC (-1,29%)
I look forward to your opinions!
